Canadian life science company MicroSintesis has raised $16.4 million in equity financing.
MicroSintesis secured the financing from Toronto-based Northern Private Capital, an investment vehicle of CFFI Ventures.
With the new capital raised, the company intends to scale-up the production of its products and also fund its international expansion.
Furthermore, MicroSintesis also plans to use the new funds to build out research capabilities and platform to deliver a new generation of microbiome products dedicated to improving livestock, companion animal, and human health.